全文获取类型
收费全文 | 2244篇 |
免费 | 217篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 83篇 |
妇产科学 | 72篇 |
基础医学 | 360篇 |
口腔科学 | 42篇 |
临床医学 | 326篇 |
内科学 | 407篇 |
皮肤病学 | 38篇 |
神经病学 | 224篇 |
特种医学 | 189篇 |
外科学 | 190篇 |
综合类 | 127篇 |
一般理论 | 5篇 |
预防医学 | 141篇 |
眼科学 | 69篇 |
药学 | 118篇 |
中国医学 | 3篇 |
肿瘤学 | 77篇 |
出版年
2022年 | 15篇 |
2021年 | 31篇 |
2020年 | 16篇 |
2019年 | 23篇 |
2018年 | 18篇 |
2017年 | 27篇 |
2016年 | 33篇 |
2015年 | 42篇 |
2014年 | 63篇 |
2013年 | 66篇 |
2012年 | 99篇 |
2011年 | 87篇 |
2010年 | 78篇 |
2009年 | 67篇 |
2008年 | 98篇 |
2007年 | 81篇 |
2006年 | 71篇 |
2005年 | 80篇 |
2004年 | 46篇 |
2003年 | 57篇 |
2002年 | 63篇 |
2001年 | 64篇 |
2000年 | 68篇 |
1999年 | 69篇 |
1998年 | 71篇 |
1997年 | 62篇 |
1996年 | 48篇 |
1995年 | 30篇 |
1994年 | 45篇 |
1993年 | 41篇 |
1992年 | 30篇 |
1991年 | 41篇 |
1990年 | 41篇 |
1989年 | 44篇 |
1988年 | 50篇 |
1987年 | 64篇 |
1986年 | 36篇 |
1985年 | 49篇 |
1984年 | 26篇 |
1983年 | 27篇 |
1982年 | 32篇 |
1981年 | 21篇 |
1980年 | 28篇 |
1979年 | 27篇 |
1978年 | 30篇 |
1977年 | 27篇 |
1976年 | 23篇 |
1975年 | 24篇 |
1974年 | 14篇 |
1967年 | 14篇 |
排序方式: 共有2479条查询结果,搜索用时 15 毫秒
991.
Although N-truncated Aβ variants are known to be the main constituent of amyloid plaques in the brains of patients with Alzheimer’s disease, their potential as targets for pharmacological intervention has only recently been investigated. In the last few years, the Alzheimer field has experienced a paradigm shift with the ever increasing understanding that targeting amyloid plaques has not led to a successful immunotherapy. On the other hand, there can be no doubt that the amyloid cascade hypothesis is central to the etiology of Alzheimer’s disease, raising the question as to why it is apparently failing to translate into the clinic. In this review, we aim to refocus the amyloid hypothesis integrating N-truncated Aβ peptides based on mounting evidence that they may represent better targets than full-length Aβ. In addition to Aβ peptides starting with an Asp at position 1, a variety of different N-truncated Aβ peptides have been identified starting with amino residue Ala-2, pyroglutamylated Glu-3, Phe-4, Arg-5, His-6, Asp-7, Ser-8, Gly-9, Tyr-10 and pyroglutamylated Glu-11. Certain forms of N-truncated species are better correlates for early pathological changes found pre-symptomatically more often than others. There is also evidence that, together with full-length Aβ, they might be physiologically detectable and are naturally secreted by neurons. Others are known to form soluble aggregates, which have neurotoxic properties in transgenic mouse models. It has been clearly demonstrated by several groups that some N-truncated Aβs dominate full-length Aβ in the brains of Alzheimer’s patients. We try to address which of the N-truncated variants may be promising therapeutic targets and which enzymes might be involved in the generation of these peptides 相似文献
992.
993.
Flumazenil: a new benzodiazepine antagonist 总被引:1,自引:0,他引:1
Flumazenil is a recently discovered pharmacologic antagonist of the CNS effects of benzodiazepines. It acts by binding CNS benzodiazepine receptors and competitively blocking benzodiazepine activation of inhibitory GABAergic synapses. Animal studies and some human studies appear to demonstrate that flumazenil has weak intrinsic agonist activity; on the other hand, studies are inconclusive in demonstrating any inverse agonist effects of this agent. Evidence available suggests that flumazenil is well tolerated in human beings over a broad range of doses when given either orally or parenterally and does not produce serious adverse effects. In the setting of isolated benzodiazepine overdose, flumazenil is capable of completely reversing coma within one to two minutes, with this effect lasting between one and five hours. Repeat doses can be given safely to reverse recurrent effects of longer-acting benzodiazepines. Flumazenil is undergoing further evaluation by the Food and Drug Administration; should this drug receive approval, it is likely to be used in emergency departments as well as in a variety of other clinical settings. First, it could be used to effect rapid reversal of benzodiazepine-induced sedation that has been administered to facilitate medical, orthopedic, and surgical procedures, particularly in the event of inadvertent respiratory depression. Second, flumazenil might have a therapeutic role in the management of patients who have taken benzodiazepine overdoses. Although most of these patients can be managed successfully with supportive therapy alone, it is possible that the use of flumazenil may obviate the need for intubation and respiratory support in such patients and eliminate the possible adverse effects of even short-term endotracheal intubation. Finally, flumazenil could have both diagnostic and therapeutic value in patients with acute alterations of mental status of unknown etiology, particularly when possible drug overdose is a consideration. Because flumazenil appears to be specific in its antagonism of benzodiazepine-induced respiratory and CNS depression, it could be used empirically to confirm or exclude a role of benzodiazepines in the generation of mental status changes in the setting of overdose or coma of unknown origin. This in turn might obviate the need for further expensive (eg, computed tomography) and sometimes invasive (eg, lumbar puncture) diagnostic modalities. This might be particularly useful because there is nothing about benzodiazepine-induced coma that clearly distinguishes it from other causes of coma; thus, there are no signs or symptoms that may reasonably allow benzodiazepine overdose to be confirmed or eliminated on clinical grounds. Further studies will continue to define the ultimate use of this new agent. 相似文献
994.
Pedrazzini A; Freedman AS; Andersen J; Heflin L; Anderson K; Takvorian T; Canellos GP; Whitman J; Coral F; Ritz J 《Blood》1989,74(6):2203-2211
In the present report we have attempted to examine immunologic reconstitution following high-dose chemoradiotherapy and anti-B-cell monoclonal antibody (MoAb)-purged autologous bone marrow transplantation (ABMT). By cell-surface phenotypic analysis, the majority of patients had normal percentage of natural killer cells (NK), monocytes, and CD8+ T cells at one month post-ABMT. In contrast, the percentage of CD4+ T cells was reduced for at least 3 years, and the CD4:CD8 ratio reflected this imbalance. B-cell reconstitution was slightly prolonged, with normal percentage and absolute numbers of CD20+ B cells evident by 3 months. Although B cells returned by 3 months, in vitro assessment of B-cell function demonstrated impairment of proliferative responses to either anti-immunoglobulins bound to beads (anti-Ig), Epstein-Barr virus (EBV), or interleukin-2 (IL-2) for approximately 1 year and low molecular B-cell growth factor (BCGF) for approximately 2 or more years. Moreover, in vivo B-cell reconstitution demonstrated a more selective defect, with normal levels of immunoglobulin IgM returning at 6 months, IgG at 12 months, and IgA after 2 years. Despite normal numbers of B cells and relative normal levels of Ig early following ABMT, our in vitro data suggest an intrinsic defect in B-cell responsiveness. Moreover, these defects are similar to those observed following nonpurged autologous and allogeneic BMT, although the interval of immune impairment appears more prolonged. 相似文献
995.
The recent trend reported by the CDC reaffirms that rubella continues to be a health care issue and should be a concern particularly for those who care for women in the childbearing age group. Immunization of all susceptible women will not only offer them protection but reduce the pool of susceptible individuals that can transmit the disease. 相似文献
996.
997.
998.
I. Bayer M.D. S. Kyzer M.D. D. Creter M.Sc. Dr. U. H. Lewinski M.D. 《Diseases of the colon and rectum》1986,29(2):123-125
Nineteen patients treated continuously with Dipyridamole® were evaluated for rectal bleeding. Thirteen suffered from overt rectal bleeding and six served as controls. Hemorrhoids were found in all patients. Contact bleeding was found in 16. The bleeding continued despite rubber band ligation, and stopped only on withdrawal of the drug. 相似文献
999.
1000.
High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast cell adhesion to activated endothelium 总被引:4,自引:1,他引:3
Spertini O; Callegari P; Cordey AS; Hauert J; Joggi J; von Fliedner V; Schapira M 《Blood》1994,84(4):1249-1256
L-selectin is expressed by most leukocytes and mediates the initial step of adhesion to vascular endothelium. A feature of this adhesion receptor is to be shed from the cell surface. We report here the presence of high levels of the shed form of L-selectin (sL-selectin) in plasma from patients with acute leukemia. We also show that sL-selectin purified from acute leukemia plasma exhibits functional activity. The mean (+/- 1 SD) plasma level of sL-selectin among 100 healthy individuals was 2.1 +/- 0.7 micrograms/mL. This value was increased (> 2 SD above the mean) in 63% of 58 patients with acute lymphoblastic leukemia (ALL) and 59% of 93 patients with acute myelogenous leukemia ([AML] P < .001). Repeated measurements in 24 patients showed normal- range levels in 16 of 16 patients in complete remission and high levels in eight of eight patients with therapy-resistant acute leukemia or leukemia relapse. Furthermore, elevated sL-selectin levels were detected in cerebrospinal fluid of three patients with ALL suffering from a relapse limited to the central nervous system. Epitope mapping with monoclonal antibodies demonstrated that L-selectin shedding from leukemic blasts was accompanied by conformational changes of its epidermal growth factor-like domain. A functional role for sL-selectin purified from leukemic plasma was supported by its ability to completely inhibit L-selectin-dependent adhesion of blast cells to tumor necrosis factor-alpha (TNF-alpha)-activated endothelium in vitro. These results suggest that sL-selectin may have an important role in the regulation of leukemic cell adhesion to endothelium. In addition, monitoring of the sL-selectin level may be useful for evaluating leukemia activity, in particular for the detection of leukemia relapse. 相似文献